WCLC 2025 - Posters & ePosters-P1.07.53 Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC : Also Effective in Patients With Multiple Prognostic Risk Factors

P1.07.53 Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC : Also Effective in Patients With Multiple Prognostic Risk Factors

Back to course

Pdf Summary

This study evaluates the efficacy and safety of aumolertinib as adjuvant therapy in patients with stage I-III non-small cell lung cancer (NSCLC) harboring EGFR mutations (EGFRm), focusing on those with multiple prognostic risk factors. Conducted at Shanghai General Hospital, the trial enrolled patients who had undergone radical surgery and were pathologically confirmed to have at least one prognostic risk factor. Patients received oral aumolertinib 110 mg once daily postoperatively until recurrence, completion of treatment, withdrawal, or discontinuation.<br /><br />Key inclusion criteria were age ≥18, ECOG performance status 0-1, stage I-III primary non-squamous NSCLC with complete resection, and EGFR mutations including exon 19 deletion or 21 L858R (alone or with other mutations). Prognostic risk factors analyzed included elderly status, high-grade tumor patterns, high-risk relapse factors, comorbidities, and ACE-27 scores. Disease-free survival (DFS) measured by investigator assessment was the primary endpoint, with overall survival (OS) and safety as secondary assessments.<br /><br />Among 52 patients, approximately half were elderly, and most had at least one high-risk factor. DFS and OS analyses found no statistically significant differences across subgroups with different individual or combined risk factors, suggesting aumolertinib’s efficacy extends regardless of multiple adverse prognostic indicators. Safety was also evaluated but detailed results were not provided in the summary.<br /><br />In conclusion, adjuvant aumolertinib 110 mg daily appears effective and tolerable for stage I-III EGFRm NSCLC patients post-surgery, including those with multiple prognostic risk factors. This supports its potential role in improving disease-free survival across diverse high-risk patient subsets. Further research with larger cohorts may help confirm these findings and refine patient selection.

Asset Subtitle

Qian Xue

Meta Tag

Speaker Qian Xue

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

aumolertinib

adjuvant therapy

non-small cell lung cancer

NSCLC

EGFR mutations

prognostic risk factors

disease-free survival

overall survival

stage I-III lung cancer

postoperative treatment